SOLTI-1904 ACROPOLI
Biomarker Program
EfficACy of Spartalizumab acROss multiPle cancer-types in patients with PD1-high mRNA expressing tumOrs defined by a singLe and pre-specIfied cutoff (ACROPOLI trial)
Phase II
Status
Recruiting
Tumour subtype:
Biomarker driven
Scenario
Localmente avanzado o metastático
Sites
HOSPITAL CLINIC DE BARCELONA, HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA, HOSPITAL DE LEÓN, HOSPITAL FUNDACIÓN JIMÉNEZ DÍAZ, HOSPITAL QUIRON DEXEUS (Instituto Oncológico Dr. Rosell), HOSPITAL UNIVERSITARI SANT JOAN DE REUS, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, ICO BADALONA, INSTITUTO VALENCIANO DE ONCOLOGÍA
